Cipher Pharmaceuticals (STU:PHE) Cyclically Adjusted Revenue per Share: €1.05 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PHE Cipher Pharmaceuticals Inc STU:PHE
89 GF Score
Price €8.70
GF Value €10.49
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Cipher Pharmaceuticals Cyclically Adjusted Revenue per Share?

Cipher Pharmaceuticals STU:PHE -1.14% 89 Cyclically Adjusted Revenue per Share is €1.05 as of Jun. 2026. GuruFocus rates STU:PHE with a GF Score™ of 89/100 and a GF Value™ of €10.49 (Modestly Undervalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cipher Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was €0.403. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.05 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Cipher Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cipher Pharmaceuticals was 27.50% per year. The lowest was 3.70% per year. And the median was 11.00% per year.

As of today (2026-08-14), Cipher Pharmaceuticals's current stock price is €8.70. Cipher Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €1.05. Cipher Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 8.29.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cipher Pharmaceuticals was 12.66. The lowest was 0.39. And the median was 2.90.


Cipher Pharmaceuticals  (STU:PHE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cipher Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8.70/1.05
=8.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cipher Pharmaceuticals was 12.66. The lowest was 0.39. And the median was 2.90.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cipher Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Cipher Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Cipher Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipher Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Cipher Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.91 1.01 1.00 1.02 1.00

Cipher Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.99 0.99 1.00 1.04 1.05

STU:PHE vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cipher Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cipher Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


STU:PHE
89GF Score
Cipher Pharmaceuticals Inc STU:PHE
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipher Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cipher Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.403/133.5265*133.5265
=0.403

Current CPI (Jun. 2026) = 133.5265.

Cipher Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.263 101.765 0.345
201612 0.215 101.449 0.283
201703 0.282 102.634 0.367
201706 0.328 103.029 0.425
201709 0.314 103.345 0.406
201712 0.384 103.345 0.496
201803 0.137 105.004 0.174
201806 0.221 105.557 0.280
201809 0.153 105.636 0.193
201812 0.205 105.399 0.260
201903 0.168 106.979 0.210
201906 0.182 107.690 0.226
201909 0.195 107.611 0.242
201912 0.197 107.769 0.244
202003 0.197 107.927 0.244
202006 0.155 108.401 0.191
202009 0.150 108.164 0.185
202012 0.184 108.559 0.226
202103 0.169 110.298 0.205
202106 0.187 111.720 0.224
202109 0.142 112.905 0.168
202112 0.197 113.774 0.231
202203 0.187 117.646 0.212
202206 0.203 120.806 0.224
202209 0.189 120.648 0.209
202212 0.181 120.964 0.200
202303 0.179 122.702 0.195
202306 0.190 124.203 0.204
202309 0.221 125.230 0.236
202312 0.182 125.072 0.194
202403 0.221 126.258 0.234
202406 0.201 127.522 0.210
202409 0.364 127.285 0.382
202412 0.432 127.364 0.453
202503 0.424 129.181 0.438
202506 0.438 129.892 0.450
202509 0.421 130.287 0.431
202512 0.406 130.366 0.416
202603 0.419 132.262 0.423
202606 0.403 133.527 0.403

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.05 mean?
Cipher Pharmaceuticals (STU:PHE) has a Cyclically Adjusted Revenue per Share of €1.05 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cipher Pharmaceuticals and its competitors.
Is Cipher Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Cipher Pharmaceuticals' current Cyclically Adjusted Revenue per Share is €1.05. Overall, Cipher Pharmaceuticals has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Cipher Pharmaceuticals' Cyclically Adjusted Revenue per Share of €1.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cipher Pharmaceuticals and its competitors. Cipher Pharmaceuticals's current Cyclically Adjusted Revenue per Share is €1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (STU:PHE) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.49, compared to a current price of €8.70 — trading 17.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.05. Cipher Pharmaceuticals' overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Cipher Pharmaceuticals (STU:PHE), the current Cyclically Adjusted Revenue per Share is €1.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipher Pharmaceuticals (STU:PHE) Overvalued in 2026?

Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued. The current stock price of €8.70 is trading 17.1% below its estimated GF Value™ of €10.49. GuruFocus considers Cipher Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:PHE:

  • Cyclically Adjusted Revenue per Share: €1.05
  • GF Value™: €10.49 vs. price of €8.70 (17.1% below fair value)
  • GF Score™: 89/100 with 7 warning signs

No single metric tells the full story. See the STU:PHE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cipher Pharmaceuticals Business Description

Address 5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
89GF Score

Get the complete analysis for STU:PHE

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.70
Price
€10.49
GF Value